Limeway Pharma Design (“Limeway”) was founded by Adrian Francis Davis, PhD. His career started in consumer healthcare, where he became Director of New Product Research, Dermatology at GSK specialising in topical dermatological design. He then founded Limeway Consultancy Partners in 2004, collaborating with over 20 international companies over the next ten years. Incorporated in 2015, “Limeway” has a strategy of integration of the best of Pharmaceutical, Cosmeceutical and Cosmetic sciences, thus, to provide robust efficacy, local tolerance/systemic safety, convenient posology (rational dosing and dose regimens) and exceptional experience in use.
Co-enhancer technologies, comprising an active, a partition coefficient (Pc) enhancer and a diffusion coefficient (Dc) enhancer as biopharmaceutically functional agents in simple cosolvent gels, are not function in typical emollient creams. PCT/GB2016/050545(GB2549418) to “Limeway” describes how selection of the chemistry of the emollient is critical to maintain enhanced skin permeation of the Dc enhancer and thus the active. Briefly, this forces formulation as a two-phase cream using silicone elastomer and fluids, which contribute an exceptional experience in consumer use.
In 2020 “Limeway” filed PCT/GB2021/051569 describing a functional co-enhancer delivery system comprising a primary active agent, which may also be nicotinamide, in combination with an ancillary user adherence-improving skin barrier restoring system comprising nicotinamide and polyhydroxy acid. Patents have been granted in several countries, most recently in Australia and New Zealand.